New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:58 EDTSLXPSalix Xifaxan data paves way for approval, says Sterne Agee
After Salix's Xifaxan drug met its primary endpoint in a study, Sterne Agee thinks the data should enable the drug to be approved as a treatment for IBS-D. The firm believes that the stock could reach $180 and it keeps a Buy rating on the stock.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent SLXP news | >>
March 16, 2015
09:22 EDTSLXPOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTSLXPValeant rises 1% after sweetening Salix takeover offer
Subscribe for More Information
08:06 EDTSLXPValeant ses Salix deal closing on April 1
08:05 EDTSLXPValeant raises offer price for Salix to $173 per share from $158
Subscribe for More Information
08:04 EDTSLXPValeant, Salix agree on amended terms to merger agreement
Subscribe for More Information
07:50 EDTSLXPSalix trading halted, pending news
Subscribe for More Information
07:50 EDTSLXPValeant to raise offer for Salix to $173 per share, DJ reports
Dow Jones cites sources.
March 13, 2015
15:50 EDTSLXPValeant announces HSR clearance for acquisition of Salix
Valeant Pharmaceuticals (VRX) announced that it has received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to its proposed acquisition of Salix Pharmaceuticals (SLXP). The expiration of the waiting period satisfies one of the conditions to consummate the tender offer and Valeant expects to be in the position to close the transaction on April 1.
13:46 EDTSLXPValeant to raise Salix bid above $160 per share after Endo entry, NYT says
In response to Endo (ENDP) making a rival bid for Salix (SLXP), Valeant Pharmaceuticals (VRX) now plans to team up with Bill Ackman's Pershing Square and other top shareholders to raises its bid for Salix to above $160 per share, all in cash, according to The New York Times, citing people briefed on the matter. The exact price of Valeantís raised offer was not yet known, the report stated. Salix shares are down about 1% to $168.88 in afternoon trading. Reference Link
13:43 EDTSLXPValeant seen hiking Salix bid above $160 per share cash, NYT says
Subscribe for More Information
10:51 EDTSLXPOptions with increasing implied volatility
Options with increasing implied volatility: PVA BBEP SLXP ENDP MYL BBBY TEVA ZTS
08:14 EDTSLXPAckman says does not view Endo bid for Salix as credible
Subscribe for More Information
08:13 EDTSLXPAckman says Endo would be very highly levered with Salix deal
Bill Ackman of Pershing Square is speaking on CNBC.
08:11 EDTSLXPAckman says Valeant CEO will not overpay for Salix
Bill Ackman of Pershing Square is speaking on CNBC.
05:47 EDTSLXPStocks with implied volatility movement; SLXP MNKD
Stocks with implied volatility movement; Salix (SLXP) 20, Teva (TEVA) 27 according to iVolatility.
March 12, 2015
11:29 EDTSLXPEndo repeats FY15 adjusted EPS view $4.35-$4.55, consensus $4.48
Subscribe for More Information
11:12 EDTSLXPOptions with increasing implied volatility
Subscribe for More Information
08:11 EDTSLXPEndo offer for Salix unlikely to trump Valeant, says Leerink
Leerink believes Endo (ENDP) is unlikely to win the acquisition of Salix (SLXP) since Valeant's (VRX) offer is in all cash and Endo's shares sold off on the news, lessening the value of its buyout proposal. The firm says the estimated deal accretion of 15%-20% may not be enough to push up Endo's stock price.
07:57 EDTSLXPValeant bid for Salix superior to Endo offer, says Canaccord
Subscribe for More Information
05:49 EDTSLXPStocks with implied volatility movement; SLXP MNKD
Subscribe for More Information
1 | 2 | all recent SLXP news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use